The study is enrolling healthy overweight and obese volunteers to evaluate the safety, tolerability, and pharmacokinetics of ascending single doses of intravenously administered trodusquemine (MSI- 1436). This ascending single-dose protocol will initially enroll approximately 35 subjects and is expected to be completed in the second half of 2007.
Jack Armstrong, president and CEO of Genaera, said: “What we learn in this first stage of clinical testing will help us understand how MSI-1436 performs in the human body and guide the determination of an optimal therapeutic dose for the larger efficacy trials which follow. The efficiency and quality of this work will be important benchmarks for Genaera moving forward.”